« Return to News | Drug Sponsors | Ethics/Regulatory

FDA says Opioids may be found in Novartis OTC drugs

Wednesday, January 11, 2012 11:25 AM

The FDA has released an advisory regarding the Novartis recall due to the mixed bottling of products. While previous reports suggested that the OTC drugs NoDoz, Excedrin, Bufferin and Gas-X had simply been mixed with each other, the FDA now is warning patients that high-powered, prescription-only opioid drugs may have found their way into Novartis OTC packaging.

The FDA said these “potent medications” include nine opioids: Opana ER, Opana, Oxymorphone, Percocet, Percodan, Endocet, Endodan, Morphine Sulfate and Zydone.

Analysts say Novartis stands to lose $560 million in sales over the next 12 months, and potentially $1.1 billion globally.

Novartis noted that Gas-X is no longer on the list of products involved in the bottling mishaps.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.